Takeda and Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival with ADCETRIS® ... Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc. today announced data from a post-hoc analysis examining progression-free survival following treatment with ADCETRIS® versus last prior therapy in patients diagnosed with relapsed or refractory Hodgkin lymphoma post-autologous stem cell transplant or relapsed or refractory systemic anaplastic large cell lymphoma .
June 19, 2013 - Business Wire via Yahoo! Finance